Correlation Effects in Side-Coupled Quantum Dots

Using Wilson's numerical renormalization group (NRG) technique we compute zero-bias conductance and various correlation functions of a double quantum dot (DQD) system. We present different regimes within a phase diagram of the DQD system. By introducing a negative Hubbard U on one of the quantum dots, we simulate the effect of electron-phonon coupling and explore the properties of the coexisting spin and charge Kondo state. In a triple quantum dot (TQD) system a multi-stage Kondo effect appears where localized moments on quantum dots are screened successively at exponentially distinct Kondo temperatures.Comment: 13 pages, 10 figure

Telemedicine in Peru as a Result of the COVID-19 pandemic: Perspective from a country with limited internet access

The COVID-19 pandemic contributed to the worldwide implementation of telemedicine because of the need for medical care for patients, especially those with chronic diseases. This perspective paper presents the current situation of telemedicine in Peru, showing advances in regulation, cases of successful implementation, and the current challenges. Access to health should be available to all, and more efforts need to be implemented to offer access to the internet to achieve high-quality telemedicine to all the vulnerable groups in Peru

Relevance of quantum fluctuations in the Anderson-Kondo model

We study a localized spin coupled to an Anderson impurity to model the situation found in higher transition metal or rare earth compounds like e.g.\ LaMnO$_3$ or Gd monopnictides. We find that, even for large quantum numbers of the localized spin, quantum fluctuations play an essential role for the case of ferromagnetic coupling between the spin and the impurity levels. For antiferromagnetic coupling, a description in terms of a classical spin is appropriate

Rob Winningham Interview 2019

In a short interview, Rob Winningham discusses his transition from Professor of Behavioral Sciences to several administrative positions at Western Oregon. Dr. Winningham considers his contributions to Western’s community, including the creation of the Academic Excellence Showcase as well as giving insight to his goals and responsibilities as Provost. Dr. Winnigham emphasizes the importance of Western Oregon’s unique academic community

Prostaglandin E2 enhances alveolar bone formation in the rat mandible

Prostaglandin E-2 (PGE(2)) induces bone formation in stress-bearing bones. The mandible, a stress-bearing bone, is loaded daily during mastication. The aim of this study was to determine if PGE(2) delivered locally to the mandible over 20 days enhances alveolar bone deposition. In 18 Lewis rats, controlled-release pellets containing PGE2 were implanted on the buccal aspect on the left-hand side of the mandible, mesial to the root of the first molar. Controlled-release pellets locally delivered 0.1, 0.05, or 0.025 mg/day of PGE2. The right side of the mandible was used as a matched control for each animal. Six sham-treated animals were implanted with a placebo pellet. On days 7 and 19, animals were injected with the bone markers tetracycline and calcein, respectively. On day 21, animals were sacrificed and undecalcified tissues obtained for morphometrical analysis. Morphometrical measurements were analyzed by paired t test to determine differences between the matched samples and one-way ANOVA to compare the different treatment groups. A significant increase in alveolar bone area was observed in mandibles treated with 0.1 and 0.05 mg/day when compared with matched controls and the placebo group. This was accompanied by a significant increase in alveolar bone height and width. The proportions of double-labeled surface (dLS), the mineral apposition rate (MAR), and bone formation rate (BFR) were significantly increased in mandibles treated with the two higher doses of PGE(2). The proportion of resorptive surface (RS) was significantly reduced in these two groups. It is concluded that PGE2 induces alveolar bone formation in the mandible when locally delivered at a dose of 0.1 or 0.05 mg/day for 20 days. (C) 2004 Elsevier Inc. All rights reserved